Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
LONDON, April 17, 2023 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical…
LONDON, April 17, 2023 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical…
LONDON, April 17, 2023 (GLOBE NEWSWIRE) — Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical…
Mr. Singer brings over 25 years of experience in biotechnology, corporate finance, mergers and acquisitions,…
Mr. Singer brings over 25 years of experience in biotechnology, corporate finance, mergers and acquisitions,…
CARSON CITY, Nev., April 17, 2023 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (“BioVie” or…
CARSON CITY, Nev., April 17, 2023 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (“BioVie” or…
WAKEFIELD, MA, April 17, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Innovation Pharmaceuticals (OTCQB:IPIX) (“the…
WAKEFIELD, MA, April 17, 2023 (GLOBE NEWSWIRE) — via NewMediaWire — Innovation Pharmaceuticals (OTCQB:IPIX) (“the…
Findings demonstrate effects of ATYR2810 in models of certain forms of lung and kidney cancers…
Findings demonstrate effects of ATYR2810 in models of certain forms of lung and kidney cancers…
Fast track designation has the potential to facilitate the development and expedite the U.S. FDA…
Fast track designation has the potential to facilitate the development and expedite the U.S. FDA…
Record revenue of approximately $2.8M expected for the three months ended March 31, 2023; 46%…
Record revenue of approximately $2.8M expected for the three months ended March 31, 2023; 46%…
Gastro Health is a leading gastroenterology group with over 380 GI physicians in the United…
Gastro Health is a leading gastroenterology group with over 380 GI physicians in the United…
Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos to become Co-Chairs of the Board…
Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos to become Co-Chairs of the Board…
– Preclinical data support the potential for FTIs in combination with KRASG12C inhibitors and TKIs…
– Preclinical data support the potential for FTIs in combination with KRASG12C inhibitors and TKIs…